loading
Precedente Chiudi:
$2.95
Aprire:
$2.92
Volume 24 ore:
359.37K
Relative Volume:
0.31
Capitalizzazione di mercato:
$187.60M
Reddito:
$488.00K
Utile/perdita netta:
$-41.44M
Rapporto P/E:
-3.0753
EPS:
-0.93
Flusso di cassa netto:
$-31.47M
1 W Prestazione:
-6.07%
1M Prestazione:
-12.92%
6M Prestazione:
-8.18%
1 anno Prestazione:
-35.76%
Intervallo 1D:
Value
$2.79
$2.92
Intervallo di 1 settimana:
Value
$2.79
$3.28
Portata 52W:
Value
$2.01
$5.6395

Cardiff Oncology Inc Stock (CRDF) Company Profile

Name
Nome
Cardiff Oncology Inc
Name
Telefono
858-952-7570
Name
Indirizzo
11055 FLINTKOTE AVENUE, SAN DIEGO, CA
Name
Dipendente
33
Name
Cinguettio
@cardiffoncology
Name
Prossima data di guadagno
2024-10-31
Name
Ultimi documenti SEC
Name
CRDF's Discussions on Twitter

Confronta CRDF con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
CRDF
Cardiff Oncology Inc
2.8699 187.60M 488.00K -41.44M -31.47M -0.93
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
503.00 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
564.47 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
634.54 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
259.48 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
248.20 24.70B 3.81B -644.79M -669.77M -6.24

Cardiff Oncology Inc Stock (CRDF) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-09-06 Iniziato Craig Hallum Buy
2022-01-05 Iniziato William Blair Outperform
2021-12-08 Iniziato Robert W. Baird Outperform
2021-08-09 Ripresa Maxim Group Buy
2020-10-22 Iniziato H.C. Wainwright Buy
2020-10-08 Iniziato Piper Sandler Overweight
Mostra tutto

Cardiff Oncology Inc Borsa (CRDF) Ultime notizie

pulisher
10:43 AM

Market Highlights: Cardiff Oncology Inc (CRDF) Ends on a High Note at 2.95 - DWinneX

10:43 AM
pulisher
Apr 27, 2025

Cardiff Oncology, Inc. (NASDAQ:CRDF) Shares Purchased by Geode Capital Management LLC - Defense World

Apr 27, 2025
pulisher
Apr 25, 2025

Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge - ADVFN

Apr 25, 2025
pulisher
Apr 24, 2025

Cardiff Oncology Inc [CRDF] Records 50-Day SMA of $3.62 - knoxdaily.com

Apr 24, 2025
pulisher
Apr 24, 2025

Market Insights: Cardiff Oncology Inc (CRDF)’s Notable Drop of -3.61, Closing at 2.94 - DWinneX

Apr 24, 2025
pulisher
Apr 24, 2025

Cardiff Oncology (CRDF) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance

Apr 24, 2025
pulisher
Apr 24, 2025

A Tale of Resilience: Cardiff Oncology Inc Amid Stock Market Turbulence - investchronicle.com

Apr 24, 2025
pulisher
Apr 23, 2025

Cardiff Oncology (CRDF) Secures New U.S. Patent for Cancer Treatment Method | CRDF Stock News - GuruFocus

Apr 23, 2025
pulisher
Apr 23, 2025

Cardiff Oncology Announces a Second Patent for the Treatment of mCRC for Bev-Naïve Patients - GlobeNewswire

Apr 23, 2025
pulisher
Apr 23, 2025

A look into Cardiff Oncology Inc (CRDF)’s deeper side - Sete News

Apr 23, 2025
pulisher
Apr 22, 2025

A closer look at Cardiff Oncology Inc (CRDF) is warranted - uspostnews.com

Apr 22, 2025
pulisher
Apr 16, 2025

Cardiff Oncology, Inc.'s (NASDAQ:CRDF) market cap touched US$186m last week, benefiting both individual investors who own 56% as well as institutions - simplywall.st

Apr 16, 2025
pulisher
Apr 15, 2025

Cardiff Oncology (CRDF) Completes Enrollment for Phase 2 Trial i - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing R - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Cardiff Wraps Up Enrollment in Phase 2 Trial of Prospective Colorectal Cancer Treatment - MarketScreener

Apr 15, 2025
pulisher
Apr 15, 2025

Cardiff Oncology Announces Completion of Enrollment in Phase 2 C - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | CRDF Stock News - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com

Apr 15, 2025
pulisher
Apr 15, 2025

Cardiff Oncology (CRDF) Completes Enrollment for Phase 2 Trial in Colorectal Cancer | CRDF Stock News - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Apr 15, 2025
pulisher
Apr 15, 2025

Cardiff Oncology Completes Patient Enrollment in Phase 2 CRDF-004 Trial for RAS-Mutated Metastatic Colorectal Cancer, Additional Data Expected in 1H 2025 - Nasdaq

Apr 15, 2025
pulisher
Apr 15, 2025

Cardiff Oncology Awards Strategic Compensation Package: Inside the Latest Employee Stock Options Grant - Stock Titan

Apr 15, 2025
pulisher
Apr 15, 2025

Cardiff Oncology Announces Completion of Enrollment in Phase 2 CRDF-004 Trial Evaluating Onvansertib for the Treatment of First-line RAS-mutated Metastatic Colorectal Cancer - GlobeNewswire

Apr 15, 2025
pulisher
Apr 15, 2025

Major Progress: First-line Colorectal Cancer Treatment Trial Hits Key Milestone - Stock Titan

Apr 15, 2025
pulisher
Apr 14, 2025

Cardiff Oncology announces positive colorectal data and $40m stock oversubscription - MSN

Apr 14, 2025
pulisher
Apr 14, 2025

Piper Sandler raises Cardiff Oncology stock target to $10 By Investing.com - Investing.com Canada

Apr 14, 2025
pulisher
Apr 14, 2025

Raymond James Financial Inc. Takes Position in Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World

Apr 14, 2025
pulisher
Apr 14, 2025

American Century Companies Inc. Raises Stock Holdings in Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World

Apr 14, 2025
pulisher
Apr 11, 2025

Metastatic Prostate Cancer Market Future Business - openPR.com

Apr 11, 2025
pulisher
Apr 05, 2025

HighTower Advisors LLC Grows Position in Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World

Apr 05, 2025
pulisher
Apr 03, 2025

Lucid Capital Markets sets $14 target on Cardiff Oncology stock By Investing.com - Investing.com Canada

Apr 03, 2025
pulisher
Apr 03, 2025

Cardiff Oncology Inc (CRDF) Has A Gold Mine On Its Hands - stocksregister.com

Apr 03, 2025
pulisher
Apr 03, 2025

Cardiff Oncology Inc [CRDF] Chief Financial Officer makes an insider purchase of 2,752 shares worth 14905.0. - knoxdaily.com

Apr 03, 2025
pulisher
Apr 01, 2025

Charles Schwab Investment Management Inc. Sells 19,629 Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World

Apr 01, 2025
pulisher
Mar 27, 2025

CRDF Shares Experience Decline in Value - knoxdaily.com

Mar 27, 2025
pulisher
Mar 26, 2025

Is Cardiff Oncology, Inc. (CRDF) The Hot Biotech Stock Under $5? - Insider Monkey

Mar 26, 2025
pulisher
Mar 24, 2025

Bank of New York Mellon Corp Increases Stock Holdings in Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World

Mar 24, 2025
pulisher
Mar 21, 2025

10 Hot Biotech Stocks Under $5 - Insider Monkey

Mar 21, 2025
pulisher
Mar 12, 2025

Is Cardiff Oncology 15% bump due to positive clinical trials or a short squeeze? - Mugglehead

Mar 12, 2025
pulisher
Mar 10, 2025

Cardiff Oncology Inc (CRDF) Q4 2024 Earnings Report Preview: Wha - GuruFocus.com

Mar 10, 2025
pulisher
Mar 10, 2025

Future Industry Growth Of Metastatic Prostate Cancer Market - openPR

Mar 10, 2025
pulisher
Mar 10, 2025

Rhumbline Advisers Buys 10,290 Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World

Mar 10, 2025
pulisher
Mar 08, 2025

Why the Global Cancer Market Could Surpass $900 Billion-And the Stocks Leading the Charge - The Malaysian Reserve

Mar 08, 2025
pulisher
Mar 05, 2025

Cardiff Oncology’s Earnings Call: Optimism Amid Challenges - MSN

Mar 05, 2025
pulisher
Mar 05, 2025

Financial Review: Kymera Therapeutics (NASDAQ:KYMR) vs. Cardiff Oncology (NASDAQ:CRDF) - Defense World

Mar 05, 2025
pulisher
Mar 04, 2025

All You Need to Know About Cardiff Oncology (CRDF) Rating Upgrade to Buy - Nasdaq

Mar 04, 2025
pulisher
Mar 03, 2025

Q1 Earnings Forecast for CRDF Issued By William Blair - Defense World

Mar 03, 2025
pulisher
Mar 03, 2025

Cardiff Oncology (NASDAQ:CRDF) Price Target Raised to $17.00 - Defense World

Mar 03, 2025
pulisher
Mar 01, 2025

HC Wainwright Forecasts Strong Price Appreciation for Cardiff Oncology (NASDAQ:CRDF) Stock - MarketBeat

Mar 01, 2025
pulisher
Mar 01, 2025

Cardiff Oncology Full Year 2024 Earnings: Beats Expectations - Yahoo Finance

Mar 01, 2025

Cardiff Oncology Inc Azioni (CRDF) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Cardiff Oncology Inc Azioni (CRDF) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Levine James E.
Chief Financial Officer
Dec 18 '24
Buy
5.00
2,400
12,000
67,716
Levine James E.
Chief Financial Officer
Dec 16 '24
Buy
3.83
2,564
9,820
62,564
TANNENBAUM RENEE P
Director
Dec 12 '24
Buy
3.42
10,000
34,224
20,000
PACE GARY W
Director
Dec 11 '24
Buy
2.60
350,115
910,299
1,047,876
PACE GARY W
Director
Dec 11 '24
Buy
2.60
11,500
29,900
1,059,376
$20.90
price up icon 1.36%
$69.80
price up icon 0.31%
$32.42
price down icon 0.60%
$24.00
price up icon 0.25%
$103.85
price down icon 0.51%
biotechnology ONC
$249.09
price down icon 0.47%
Capitalizzazione:     |  Volume (24 ore):